Kimberly Nguyen
Family · Neosho, MONPI 1215287750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,498 and has fallen 96.4% since, to $89 in 2025.
Across 244 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$459
- AstraZeneca$375
- Lilly USA, LLC$360
- Pfizer$346
- Novo Nordisk$253
- Amgen$249
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,454100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $459 |
| AstraZeneca | 20 | $375 |
| Lilly USA, LLC | 27 | $360 |
| Pfizer | 24 | $346 |
| Novo Nordisk | 24 | $253 |
| Amgen | 18 | $249 |
| Johnson & Johnson | 18 | $218 |
| Bayer | 6 | $116 |
| Axsome Therapeutics, Inc. | 1 | $100 |
| Antares Pharma, Inc. | 6 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Dexcom, Inc. | 4 | $72 |
| Abbott | 3 | $70 |
| Astellas Pharma US Inc | 4 | $68 |
| Nestle Healthcare Nutrition Inc. | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| GSK | 4 | $54 |
| Organogenesis Inc. | 3 | $53 |
| Boehringer Ingelheim | 4 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Novartis | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $25 |
| Exact Sciences | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$3,454 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in Neosho
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.